AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Summary: The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J’s Carvykti, although Wall Street analysts were divided on how the two drugs compare.
Summary: Investigators judged the death to be related to busulfan, an old chemotherapy drug that’s used to prepare patients for infusion with CRISPR therapies like Beam’s.
Summary: Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech’s down market has made the company’s journey difficult.
Summary: VTR Biotech announces the upgrade of its National Enterprise Technology Center. Founded in the early 1990s, the company has grown into a leading biotechnology innovator in China.
Summary: Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid therapy suzetrigine in pain—both slated for January 2025.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
